×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: eczema | treatment | Rinvoq | Cibinqo | FDA

FDA Approves Two New Drugs to Treat Eczema

man itches eczema on his hands
(Dreamstime)

Friday, 14 January 2022 04:19 PM

The U.S. Food and Drug Administration approved drugs from AbbVie Inc and Pfizer Inc for treating eczema, a skin disease, the companies said on Friday.

AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic dermatitis, or eczema, in patients who do not respond to previous treatment or when use of other treatments is not recommended.

Rinvoq's approval was expanded from rheumatoid arthritis to treat eczema for patients 12 years and older, while Cibinqo was approved for use in only adults.

Both the drugs belong to a class called JAK inhibitors, which block inflammation-causing enzymes known as Janus kinases and target a range of autoimmune diseases.

Both Pfizer and AbbVie cited risks of serious infections and cardiovascular events, among others.

The expanded approval for Rinvoq follows significant delays amid concerns over safety of JAK inhibitors.

Cibinqo had last year received approvals from the European and UK regulators.

The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer, Eli Lilly and AbbVie following a review of Pfizer's Xeljanz, another JAK inhibitor.

The initial results from a trial showed an increased risk of serious heart-related problems and cancer in some patients being treated with the drug. 

© 2022 Thomson/Reuters. All rights reserved.


Health-News
The U.S. Food and Drug Administration approved drugs from AbbVie Inc and Pfizer Inc for treating eczema, a skin disease, the companies said on Friday.AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic dermatitis, or eczema, in...
eczema, treatment, Rinvoq, Cibinqo, FDA
202
2022-19-14
Friday, 14 January 2022 04:19 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved